Your shopping cart is currently empty

MSDC-0602K (Azemiglitazone potassium) (Azemiglitazone potassium) is a PPARγ-sparing thiazolidinedione (Ps-TZD) compound that binds to PPARγ with an IC50 of 18.25 μM. It also modulates the mitochondrial pyruvate carrier (MPC). This compound, MSDC-0602K, has potential applications in researching fatty liver conditions, including dysfunctional lipid metabolism, inflammation, and insulin resistance. MSDC-0602K acts as an insulin sensitizer, improving insulinemia and fatty liver disease in mice both individually and in combination with Liraglutide.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $55 | In Stock | In Stock | |
| 5 mg | $123 | In Stock | In Stock | |
| 10 mg | $196 | In Stock | In Stock | |
| 25 mg | $392 | In Stock | In Stock | |
| 50 mg | $629 | In Stock | In Stock | |
| 100 mg | $886 | In Stock | In Stock | |
| 500 mg | $1,770 | - | In Stock |
| Description | MSDC-0602K (Azemiglitazone potassium) (Azemiglitazone potassium) is a PPARγ-sparing thiazolidinedione (Ps-TZD) compound that binds to PPARγ with an IC50 of 18.25 μM. It also modulates the mitochondrial pyruvate carrier (MPC). This compound, MSDC-0602K, has potential applications in researching fatty liver conditions, including dysfunctional lipid metabolism, inflammation, and insulin resistance. MSDC-0602K acts as an insulin sensitizer, improving insulinemia and fatty liver disease in mice both individually and in combination with Liraglutide. |
| Targets&IC50 | PPARγ:18.25 μM |
| In vivo | Diabetic db/db and MS-NASH mice are treated with MSDC-0602K via oral gavage, Liraglutide via s.c. injection, or a combination of MSDC-0602K + Liraglutide. This combination treatment may be an effective therapeutic strategy for diabetes and non-alcoholic steatohepatitis. Animal Model: Five-week-old male db/db mice on C57BL/6J background and age/sex-matched db/+ control mice [1]. Dosage: 30 mg/kg MSDC-0602K and 0.2 mg/kg Liraglutide. Administration: MSDC-0602K gavage daily, Liraglutide s.c. every other day, or combined MSDC-0602K + Liraglutide. Result: MSDC-0602K alone corrected glycemia and reduced insulinemia, while the combination with Liraglutide significantly improved glucose tolerance and liver histology[1]. |
| Synonyms | MSDC-0602K, Azemiglitazone potassium |
| Molecular Weight | 409.5 |
| Formula | C19H16KNO5S |
| Cas No. | 1314533-27-1 |
| Smiles | COC1=CC=CC(=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)[N-]C(=O)S3.[K+] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (122.1 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.